| 发明名称 | Respiratory disease treatment | ||
| 摘要 | A pharmaceutical composition adapted for pulmonary administration by inhalation is described, wherein the composition comprises a glitazone and one or more pharmaceutically acceptable carriers and/or excipients, wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer, and wherein the glitazone is pioglitazone or rosiglitazone or a pharmaceutically acceptable salt thereof, and wherein the glitazone is in the form of microparticles. | ||
| 申请公布号 | US9078885(B2) | 申请公布日期 | 2015.07.14 |
| 申请号 | US201414246695 | 申请日期 | 2014.04.07 |
| 申请人 | Pulmagen Therapeutics (Inflammation) Limited | 发明人 | Finch Harry;Fox Craig;Sajad Mohammed;Bondil Van Niel Monique;Forrest Andrew |
| 分类号 | A01N43/00;A61K31/33;A61K31/4439;A61K9/00;A61K45/06;A61K31/56;A61K31/573;A61K31/58 | 主分类号 | A01N43/00 |
| 代理机构 | Morgan, Lewis & Bockius LLP | 代理人 | Morgan, Lewis & Bockius LLP |
| 主权项 | 1. A pharmaceutical composition adapted for pulmonary administration by inhalation, the composition comprising a glitazone and one or more pharmaceutically acceptable carriers and/or excipients, wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer, wherein the glitazone is pioglitazone or rosiglitazone or a pharmaceutically acceptable salt thereof, wherein the glitazone is in the form of microparticles having an equivalent d50 average particle size of less than 10 μm, and wherein the pharmaceutical composition is selected from the group consisting of a suspension and an aerosol. | ||
| 地址 | Buckinghamshire GB | ||